Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Legend Biotech ( (LEGN) ).
On January 20, 2026, Legend Biotech Corporation reshaped its boardroom, appointing GenScript chairman and executive director Robin Meng as a Class III director to serve until the company’s 2026 annual general meeting, replacing outgoing director Li Zhu. On the same date, directors Li Zhu and Yau Wai Man Philip resigned from the board, with the company emphasizing that their departures did not stem from any dispute over operations or policies; in recognition of Yau’s contributions, the board’s compensation committee approved accelerated vesting of his remaining restricted share units and a one-time cash payment of $56,250 for his foregone 2026 board fees, while appointing Tomas Heyman as the new chair of the audit committee, signaling a continuation of board refreshment and governance continuity amid close alignment with major shareholder GenScript.
The most recent analyst rating on (LEGN) stock is a Hold with a $21.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.
Spark’s Take on LEGN Stock
According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.
The score is most constrained by weak financial performance (ongoing losses and negative operating/free cash flow) and bearish technicals (price below major moving averages with negative MACD). These are partially offset by a positive earnings-call outlook driven by strong CARVYKTI growth, expanding international demand, and improved labeling that could support the path to profitability.
To see Spark’s full report on LEGN stock, click here.
More about Legend Biotech
Legend Biotech Corporation is a biotechnology company focused on the life sciences sector, operating out of Somerset, New Jersey. The company develops advanced biopharmaceutical products and maintains close strategic and financial ties with GenScript, its largest shareholder, through a series of related-party agreements disclosed in its regulatory filings.
Average Trading Volume: 2,280,027
Technical Sentiment Signal: Sell
Current Market Cap: $4.33B
For an in-depth examination of LEGN stock, go to TipRanks’ Overview page.